久保秀司 (Shuji Kubo) - マイポータル

基本情報

遺伝性難病・難治性癌に対し遺伝子細胞治療やウイルス療法の研究を行なっている。

A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma

Tomoki Yamano, Shuji Kubo, Naohiro Tomita

Cancer Medicine 9(10) 3337 - 3343 2020年5月13日査読有り
Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy.

Yamano T, Kubo S, Yano A, Kominato T, Tanaka S, Ikeda M, Tomita N

Oncotarget 10(3) 352 - 367 2019年1月査読有り
Dual-vector prodrug activator gene therapy using retroviral replicating vectors.

Kubo S, Takagi-Kimura M, Tagawa M, Kasahara N

Cancer gene therapy 2018年10月査読有り
Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors.

Kubo S, Takagi-Kimura M, Kasahara N

Cancer gene therapy 26(1-2) 41 - 47 2018年7月査読有り
Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes

Suguru Yamauchi, Boya Zhong, Kiyoko Kawamura, Shan Yang, Shuji Kubo, Masato Shingyoji, Ikuo Sekine, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Masatoshi Tagawa

BMC CANCER 17(1) 622 2017年9月査読有り

Retroviral replicating vector-mediated prodrug activator gene therapy in an experimental model of human osteosarcoma

S. Kubo, M. Takagi-Kimura, N. Kasahara

HUMAN GENE THERAPY 28(12) A28 - A29 2017年12月
An Inhibitor for the MDM2-p53 Interaction Produces Synergistic Cytotoxicity with Oncolytic Adenoviruses on Mesothelioma with Wild-Type p53 Genotype

Masatoshi Tagawa, Thao T. T. Nguyen, Takao Morinaga, Boya Zhong, Michiko Hanazono, Shuji Kubo, Masato Shingyoji, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima

MOLECULAR THERAPY 25(5) 280 - 280 2017年5月
Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors in an Experimental Model of Human Osteosarcoma

Shuji Kubo, Misato Takagi-Kimura, Noriyuki Kasahara

MOLECULAR THERAPY 25(5) 61 - 61 2017年5月
E1B-55kDa-defective adenoviruses produced cytotoxicity in combination with MDM2 inhibitors on INK4A/ARF-defective mesothelioma

Y. Tada, T. T. Nguyen, S. Kubo, M. Shingyoji, I. Sekine, K. Tatsumi, H. Shimada, K. Hiroshima, M. Tagawa

HUMAN GENE THERAPY 27(11) A89 - A89 2016年11月
Customization of virotherapy with retroviral replicating vectors on the basis of cellular receptor expression profiles

S. Kubo, Y. Mawatari-Furukawa, N. Kasahara

HUMAN GENE THERAPY 27(11) A82 - A82 2016年11月